Blacksburg, Virginia, September 6, 2011. Intrexon Corporation, a privately held synthetic biology company, today announced being named by FierceBiotech as one of 2011’s Fierce 15, designating it as one of the most promising private biotechnology companies in the industry.
“Intrexon is dedicated to realizing the exceptional advantages of our Better DNA™ technology in a variety of host cell applications and to expanding the possibilities of what can be accomplished through the engineering of biology. Being named a Fierce 15 company is an appreciated recognition of both our advanced technology and the dedication of our nearly 300 team members,” stated Intrexon Corporation Chairman and CEO, Randal J. Kirk.
“Everybody talks about revolution in the tech world, but Intrexon’s Randal Kirk is marshaling the troops around the banner of synthetic biology, promising to forge a whole new approach to drug development and upending the apple cart on the manufacturing end,” says John Carroll, editor-in-chief of FierceBiotech. “Right now he’s looking for just the right set of partners to help make it all happen. And the companies that Intrexon chooses to partner with help define what the Fierce 15 is all about.”
An internationally recognized daily newsletter reaching more than 90,000 biotech and pharma industry professionals, FierceBiotech evaluates hundreds of private companies for its annual list, which is based on a variety of factors such as the strength of its technology, partnerships, venture backers and a competitive market position.
The Fierce 15 celebrates the spirit of being "fierce" – championing innovation and creativity, even in the face of intense competition. A complete list of “Fierce 15” companies—the online newsletter’s ninth annual selection--is available online at www.fiercebiotech.com.
About Intrexon Corporation
Intrexon Corporation is a privately held synthetic biology company that employs modular DNA control systems to enhance capabilities, improve safety and lower cost in human therapeutics, protein production, industrial products, agricultural biotechnology, and animal science. The company’s advanced transgene engineering platform enables Better DNA™ technology by combining revolutionary DNA control systems with corresponding advancements in modular transgene design, assembly and optimization. More information about the company is available at www.DNA.com.
FierceBiotech is the biotech industry's daily monitor - a free email newsletter and web resource providing the latest biotech news, articles, and resources related to clinical trials, drug discovery, FDA approval and regulation, biotech company deals and more. More than 90,000 top biotech professionals rely on FierceBiotech for an insider briefing on the day’s top stories. Sign up is free at www.fiercebiotech.com.